EB 160
Alternative Names: EB-160Latest Information Update: 24 Jun 2022
At a glance
- Originator Shanghai Euregen Biopharma
- Class Antineoplastics
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer